Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:CUTR's Cash-to-Debt is ranked higher than
98% of the 335 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. NAS:CUTR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CUTR' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.67
NAS:CUTR's Equity-to-Asset is ranked higher than
55% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. NAS:CUTR: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CUTR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.81 Max: 0.87
Current: 0.67
0.31
0.87
Interest Coverage No Debt
NAS:CUTR's Interest Coverage is ranked higher than
97% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. NAS:CUTR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:CUTR' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 8.96
Beneish M-Score: -1.96
WACC vs ROIC
3.77%
46.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 2.53
NAS:CUTR's Operating Margin % is ranked higher than
50% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. NAS:CUTR: 2.53 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CUTR' s Operating Margin % Range Over the Past 10 Years
Min: -20.83  Med: -7.94 Max: 9.39
Current: 2.53
-20.83
9.39
Net Margin % 2.89
NAS:CUTR's Net Margin % is ranked higher than
54% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NAS:CUTR: 2.89 )
Ranked among companies with meaningful Net Margin % only.
NAS:CUTR' s Net Margin % Range Over the Past 10 Years
Min: -32.93  Med: -7.42 Max: 10.33
Current: 2.89
-32.93
10.33
ROE % 6.66
NAS:CUTR's ROE % is ranked higher than
61% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. NAS:CUTR: 6.66 )
Ranked among companies with meaningful ROE % only.
NAS:CUTR' s ROE % Range Over the Past 10 Years
Min: -16.6  Med: -6.99 Max: 9.59
Current: 6.66
-16.6
9.59
ROA % 4.38
NAS:CUTR's ROA % is ranked higher than
66% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.33 vs. NAS:CUTR: 4.38 )
Ranked among companies with meaningful ROA % only.
NAS:CUTR' s ROA % Range Over the Past 10 Years
Min: -13.66  Med: -5.3 Max: 7.71
Current: 4.38
-13.66
7.71
ROC (Joel Greenblatt) % 44.48
NAS:CUTR's ROC (Joel Greenblatt) % is ranked higher than
83% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.51 vs. NAS:CUTR: 44.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CUTR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1247.08  Med: -223.26 Max: 140.19
Current: 44.48
-1247.08
140.19
3-Year Revenue Growth Rate 18.40
NAS:CUTR's 3-Year Revenue Growth Rate is ranked higher than
83% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. NAS:CUTR: 18.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CUTR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18.1  Med: 10.1 Max: 54.9
Current: 18.4
-18.1
54.9
GuruFocus has detected 3 Warning Signs with Cutera Inc $NAS:CUTR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CUTR's 30-Y Financials

Financials (Next Earnings Date: 2017-08-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:RTIX, AMEX:CVRS, NAS:VRAY, OTCPK:IPDQF, NAS:ARAY, NAS:ELOS, OTCPK:XVIPF, NYSE:IVC, NAS:EXAC, NAS:TCMD, NAS:OBLN, NAS:FONR, NAS:AXGN, NAS:VIVE, OTCPK:SOMNF, OTCPK:PHMZF, NAS:NVTR, NAS:SPNE, OTCPK:IMMNF, NAS:NVCN » details
Traded in other countries:TJ9.Germany,
Headquarter Location:USA
Cutera Inc is a medical device company. The Company is engaged in designing, development, manufacturing, marketing and servicing of laser and other energy based aesthetics systems for practitioners.

Cutera Inc was established in the San Francisco Bay Area in 1998. It is a medical device company, specializing in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners. It offers easy-to-use products based on four main platforms/systems Xeo, GenesisPlus, ExcelV, and truSculpt, each of which enables physicians and other qualified practitioners to perform safe and effective aesthetic procedures for their customers. The Xeo is a multi-application platform on which a customer can purchase hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, improving texture, reducing pore size, and treating fine lines and laxity. GenesisPlus platform, is a dedicated laser system for performing aesthetic skin procedures and for the temporary increase of clear nail in patients with onychomycosis, or toenail fungus. ExcelV is a high-performance, vascular platform designed specifically for the core-market of Dermatologists and Plastic Surgeons. This platform provides a combination of the 532 nm green laser with Cutera's award-winning 1064 nm Nd:YAG technology, to provide a single, compact and efficient system that treats the entire range of cosmetic vascular conditions, without the need for costly consumables. truSculpt is a high-powered radio frequency platform designed for the non-invasive body contouring market. This system is designed to treat all body areas and with its electrode design is able to achieve comfortable, uniform heating of the subcutaneous fat. In the U.S. its markets and sells its products mainly through a direct sales organization. International sales are generally made through a distributor network in over 60 countries. As of December 31, 2013, the Company had 30 issued U.S. patents and 11 pending U.S. patent applications. Its registered trademarks include Cutera, Acutip 500, CoolGlide, CoolGlide Excel, Limelight, myQ, Pearl, ProWave 770, ProWave LX, Solera, Titan, Xeo and truSculpt. The Company's products competes against laser and other energy-based products offered by public companies, such as Cynosure, Elen (in Italy), Lumenis, Syneron and Zeltiq, as well as private companies, including, Alma, Sciton, and several others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, as well as other regulatory bodies.

Top Ranked Articles about Cutera Inc

Cutera to Host Analyst & Investor Day on June 14, 2017
Cutera Names Darren W. Alch, Vice President, General Counsel and Secretary
CUTERA Launches truSculpt® 3D … A New Dimension in Body Sculpting
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cutera, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Cutera, Inc. to Announce Results for the First Quarter Ended March 31, 2017
Cutera Announces Preliminary Financial Results for First Quarter of 2017 and Planned Management Change
Cutera to Present at the Sidoti & Company Spring 2017 Convention

BRISBANE, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Cutera, Inc. (NASDAQ:CUTR), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, announced today that James Reinstein, President and Chief Executive Officer, will be presenting at the Spring 2017 Sidoti Convention, to be held on March 29, 2017 at the Marriott Marquis in Times Square in New York, NY.
Mr. Reinstein is scheduled to present on Wednesday, March 29 at 1:15 PM ET. A live audio webcast and slides of the presentation will be made available at the Investor Relations section of the Company’s website, www.cutera.com. About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
CONTACTS:

Cutera, Inc.
Ron Santilli
Chief Financial Officer
415-657-5500

Investor Relations
John Mills
Integrated Corporate Relations, Inc.
646-277-1254
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 95.94
CUTR's PE Ratio is ranked lower than
86% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 31.71 vs. CUTR: 95.94 )
Ranked among companies with meaningful PE Ratio only.
CUTR' s PE Ratio Range Over the Past 10 Years
Min: 14.53  Med: 75 Max: 639
Current: 95.94
14.53
639
Forward PE Ratio 54.35
CUTR's Forward PE Ratio is ranked lower than
86% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. CUTR: 54.35 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 95.94
CUTR's PE Ratio without NRI is ranked lower than
87% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 31.15 vs. CUTR: 95.94 )
Ranked among companies with meaningful PE Ratio without NRI only.
CUTR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.53  Med: 75 Max: 639
Current: 95.94
14.53
639
PB Ratio 6.07
CUTR's PB Ratio is ranked lower than
75% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. CUTR: 6.07 )
Ranked among companies with meaningful PB Ratio only.
CUTR' s PB Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.58 Max: 6.09
Current: 6.07
0.68
6.09
PS Ratio 2.93
CUTR's PS Ratio is ranked higher than
56% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.36 vs. CUTR: 2.93 )
Ranked among companies with meaningful PS Ratio only.
CUTR' s PS Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.94 Max: 5.61
Current: 2.93
0.93
5.61
Price-to-Free-Cash-Flow 294.30
CUTR's Price-to-Free-Cash-Flow is ranked lower than
96% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 32.05 vs. CUTR: 294.30 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CUTR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.78  Med: 61.5 Max: 1266
Current: 294.3
9.78
1266
Price-to-Operating-Cash-Flow 208.86
CUTR's Price-to-Operating-Cash-Flow is ranked lower than
98% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 20.50 vs. CUTR: 208.86 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CUTR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.28  Med: 45.91 Max: 431.11
Current: 208.86
9.28
431.11
EV-to-EBIT 98.42
CUTR's EV-to-EBIT is ranked lower than
94% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 24.85 vs. CUTR: 98.42 )
Ranked among companies with meaningful EV-to-EBIT only.
CUTR' s EV-to-EBIT Range Over the Past 10 Years
Min: -3233.4  Med: -3.7 Max: 695.7
Current: 98.42
-3233.4
695.7
EV-to-EBITDA 74.88
CUTR's EV-to-EBITDA is ranked lower than
94% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 18.30 vs. CUTR: 74.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
CUTR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -503.2  Med: -3.3 Max: 172.5
Current: 74.88
-503.2
172.5
Current Ratio 3.21
CUTR's Current Ratio is ranked higher than
61% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. CUTR: 3.21 )
Ranked among companies with meaningful Current Ratio only.
CUTR' s Current Ratio Range Over the Past 10 Years
Min: 2.5  Med: 6.58 Max: 9.09
Current: 3.21
2.5
9.09
Quick Ratio 2.61
CUTR's Quick Ratio is ranked higher than
62% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. CUTR: 2.61 )
Ranked among companies with meaningful Quick Ratio only.
CUTR' s Quick Ratio Range Over the Past 10 Years
Min: 2.21  Med: 6.02 Max: 8.66
Current: 2.61
2.21
8.66
Days Inventory 102.27
CUTR's Days Inventory is ranked higher than
64% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 131.96 vs. CUTR: 102.27 )
Ranked among companies with meaningful Days Inventory only.
CUTR' s Days Inventory Range Over the Past 10 Years
Min: 66.49  Med: 104.48 Max: 137.01
Current: 102.27
66.49
137.01
Days Sales Outstanding 52.18
CUTR's Days Sales Outstanding is ranked higher than
75% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. CUTR: 52.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
CUTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.62  Med: 40.06 Max: 52.18
Current: 52.18
22.62
52.18
Days Payable 20.98
CUTR's Days Payable is ranked lower than
88% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 55.39 vs. CUTR: 20.98 )
Ranked among companies with meaningful Days Payable only.
CUTR' s Days Payable Range Over the Past 10 Years
Min: 17.66  Med: 20.42 Max: 36.15
Current: 20.98
17.66
36.15

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.40
CUTR's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. CUTR: 0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CUTR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: -2.45 Max: 3
Current: 0.4
-13.6
3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 18.37
CUTR's Price-to-Net-Cash is ranked lower than
54% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 15.77 vs. CUTR: 18.37 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CUTR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.2  Med: 2.64 Max: 18.44
Current: 18.37
1.2
18.44
Price-to-Net-Current-Asset-Value 6.49
CUTR's Price-to-Net-Current-Asset-Value is ranked higher than
54% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. CUTR: 6.49 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CUTR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.91  Med: 2.02 Max: 23.73
Current: 6.49
0.91
23.73
Price-to-Tangible-Book 6.20
CUTR's Price-to-Tangible-Book is ranked lower than
62% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 3.91 vs. CUTR: 6.20 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CUTR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.77  Med: 1.89 Max: 20.68
Current: 6.2
0.77
20.68
Price-to-Intrinsic-Value-Projected-FCF 18.37
CUTR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
95% of the 143 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. CUTR: 18.37 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CUTR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.29 Max: 1308
Current: 18.37
0.45
1308
Price-to-Median-PS-Value 1.51
CUTR's Price-to-Median-PS-Value is ranked lower than
73% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. CUTR: 1.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CUTR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.08 Max: 2.72
Current: 1.51
0.56
2.72
Price-to-Graham-Number 5.14
CUTR's Price-to-Graham-Number is ranked lower than
75% of the 142 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. CUTR: 5.14 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CUTR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.93  Med: 2.02 Max: 7.76
Current: 5.14
0.93
7.76
Earnings Yield (Greenblatt) % 0.99
CUTR's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. CUTR: 0.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CUTR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -224.8  Med: -8 Max: 795.7
Current: 0.99
-224.8
795.7

More Statistics

Revenue (TTM) (Mil) $124.93
EPS (TTM) $ 0.27
Beta0.27
Short Percentage of Float2.01%
52-Week Range $10.42 - 24.95
Shares Outstanding (Mil)13.86

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 140 161 185
EPS ($) 0.45 0.70 1.05
EPS without NRI ($) 0.45 0.70 1.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
39.60%
Dividends per Share ($)
» More Articles for CUTR

Headlines

Articles On GuruFocus.com
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 
Stocks That Fell to 3-Year Lows in the Week of June 23 Jun 24 2017 
Weekly Top Insider Buys Highlight for the Week of June 23 Jun 24 2017 
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 
Delta and Korean Air Create Leading trans-Pacific Joint Venture Jun 23 2017 
Harwood Feffer LLP Announces Investigation of EnerNOC, Inc. Jun 23 2017 

More From Other Websites
Cutera to Host Analyst & Investor Day on June 14, 2017 Jun 08 2017
Cutera Names Darren W. Alch, Vice President, General Counsel and Secretary Jun 05 2017
ETFs with exposure to Cutera, Inc. : June 2, 2017 Jun 02 2017
Cutera (CUTR) Shows Strength: Stock Adds 5.4% in Session May 26 2017
Edited Transcript of CUTR earnings conference call or presentation 1-May-17 9:00pm GMT May 23 2017
CUTERA Launches truSculpt® 3D … A New Dimension in Body Sculpting May 16 2017
ETFs with exposure to Cutera, Inc. : May 4, 2017 May 04 2017
Cutera, Inc. :CUTR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 May 03 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cutera, Inc. for Potential... May 02 2017
Cutera reports 1Q loss May 01 2017
Cutera Reports First Quarter 2017 Financial Performance May 01 2017
Investor Network: Cutera, Inc. to Host Earnings Call May 01 2017
Cutera, Inc. to Announce Results for the First Quarter Ended March 31, 2017 Apr 25 2017
Cutera Announces Preliminary Financial Results for First Quarter of 2017 and Planned Management... Apr 20 2017
ETFs with exposure to Cutera, Inc. : April 17, 2017 Apr 17 2017
Cutera, Inc. :CUTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Why Cutera (CUTR) Stock Might be a Great Pick Feb 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}